Smith & Nephew (NYSE:SNN)‘s stock had its “buy” rating reissued by analysts at Berenberg Bank in a note issued to investors on Tuesday, The Fly reports.
SNN has been the subject of several other reports. Zacks Investment Research upgraded shares of Smith & Nephew from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 27th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Smith & Nephew in a report on Monday, February 22nd. Barclays reaffirmed an “overweight” rating on shares of Smith & Nephew in a report on Friday. Canaccord Genuity increased their price target on Smith & Nephew from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Friday. Finally, Commerzbank lowered Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Monday, February 22nd. Two analysts have rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $47.83.
Shares of NYSE:SNN traded down $1.26 during midday trading on Tuesday, hitting $42.24. 28,842 shares of the stock were exchanged, compared to its average volume of 484,845. The business’s 50-day moving average price is $39.28 and its 200 day moving average price is $40.46. Smith & Nephew has a 12 month low of $34.29 and a 12 month high of $46.10. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.04 and a current ratio of 2.18. The stock has a market capitalization of $18.56 billion, a price-to-earnings ratio of 20.71, a P/E/G ratio of 4.91 and a beta of 0.70.
Smith & Nephew Company Profile
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures.
Featured Article: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.